⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REPL News
Replimune Group, Inc.
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
globenewswire.com
REPL
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
globenewswire.com
REPL
Form 8-K
sec.gov
REPL
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
globenewswire.com
REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
accessnewswire.com
REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
accessnewswire.com
REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
accessnewswire.com
REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
accessnewswire.com
REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
prnewswire.com
REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
accessnewswire.com
REPL